Intuity Medical and embecta Launch Commercial Collaboration, Expanding Access to Self-Management Innovations for People With Diabetes
November 07 2022 - 5:50AM
Intuity Medical, Inc. and Embecta Corp. (“embecta”) (NASDAQ: EMBC)
today announced they have signed a co-promotional agreement under
which embecta sales representatives will be able to promote Intuity
Medical’s innovative POGO Automatic® Blood Glucose Monitoring
System to healthcare professionals they call on within the U.S.,
effective immediately.
Both companies are dedicated to improving the lives of people
with diabetes. Having spun off from BD (Becton, Dickinson and
Company) in April of this year, embecta is one of the world’s
largest pure-play diabetes companies and, with a nearly 100-year
history of leadership in insulin delivery, well established across
the U.S. market. Intuity Medical is a medical technology company
focused on the development and commercialization of seamless and
intuitive blood glucose monitoring solutions.
“We are excited to partner with an established leader like
embecta that has such extensive experience serving people with
diabetes,” said George Zamanakos, President and CEO of Intuity
Medical. “Working closely with the embecta team will help us expand
where we’re able to offer POGO Automatic, giving a new option for
simplifying diabetes to millions of people currently relying on
conventional blood glucose meters.”
With its 10-test cartridge technology, POGO Automatic is the
only FDA-cleared automatic blood glucose monitor (ABGM) that
lances, collects blood, and produces a glucose result at the push
of one button, ending the need to individually load and then
dispose of lancets and test strips. Being able to offer POGO
Automatic will expand the innovation and breadth of embecta’s
diabetes care offerings.
“The agreement to promote POGO Automatic to healthcare
professionals not only enables us to expand our offerings to
physicians we call on, but it does so within an innovative new
category,” said Tom Blount, Senior Vice President and President,
North America, for embecta. “Automatic blood glucose monitoring is
transforming this vital aspect of self-management into something
truly seamless and simple for people with diabetes.”
About Intuity Medical, Inc.
Intuity Medical, Inc. is a commercial-stage medical technology
company focused on developing innovative solutions to improve the
health and quality of life of people with diabetes. Headquartered
in Fremont, California, the company strives to simplify diabetes
management and was founded with the mission of making life with
diabetes easier. Intuity Medical’s POGO Automatic® Blood Glucose
Monitoring System is the only FDA-cleared automatic blood glucose
monitoring system that lances and collects blood in just one step
with 10-test cartridge technology, ending the need to individually
load lancets and test strips (as required by conventional blood
glucose meters). POGO Automatic delivers a much simplified and
discreet blood glucose testing experience that is less disruptive
to the everyday lives of people with diabetes. To learn more,
please visit www.presspogo.com.
About embecta
embecta, formerly part of BD (Becton, Dickinson and Company), is
one of the largest pure-play diabetes care companies in the world,
leveraging its nearly 100-year legacy in insulin delivery to
empower people with diabetes to live their best life through
innovative solutions, partnerships and the passion of more than
2,000 employees around the globe. For more information,
visit embecta.com.
CONTACTS
Media (for Intuity Medical):Jeff
Christensen831-566-0275publicrelations@intuitymedical.com
Media (for embecta):Christian GlazarSr.
Director, Corporate Communications908-821-6922Contact Media
Relations
embecta Investors:Pravesh KhandelwalVP, Head of
Investor Relations551-264-6547Contact IR
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/3dad0bdb-c92d-4dd4-834e-12f508ea494d
Embecta (NASDAQ:EMBCV)
Historical Stock Chart
From Jan 2025 to Feb 2025
Embecta (NASDAQ:EMBCV)
Historical Stock Chart
From Feb 2024 to Feb 2025